Additional file 1 of A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma

Additional file 1: Table S1. Detailed description of RCTs. RCT, randomized controlled trial; ITT, intention-to-treat; OS, overall survival; EFS, event-free survival; DFS, disease-free survival; VCR, vincristine; ActD, actinomycin D; CPA, cyclophosphamide; ADM (DOX), doxorubicin; IFM, ifosfamide; ETP, etoposide; VAC, VCR + ActD+CPA; VACA, VCR + ActD+CPA + ADM; VAIA, VCR + ActD+IFM + ADM; VAI, VCR + ActD+IFM; VDC, VCR + doxorubicin+CPA; IE, IFM + ETP; EVAIA, ETP + VCR + ActD+IFM + ADM.

补充材料1：表S1。随机对照试验（randomized controlled trial, RCT）详细说明。相关术语定义如下：意向治疗分析（intention-to-treat, ITT）、总生存期（overall survival, OS）、无事件生存期（event-free survival, EFS）、无病生存期（disease-free survival, DFS）、长春新碱（vincristine, VCR）、放线菌素D（actinomycin D, ActD）、环磷酰胺（cyclophosphamide, CPA）、多柔比星（doxorubicin, ADM (DOX)）、异环磷酰胺（ifosfamide, IFM）、依托泊苷（etoposide, ETP）、VAC方案（VCR + ActD+CPA，即长春新碱+放线菌素D+环磷酰胺）、VACA方案（VCR + ActD+CPA + ADM，即长春新碱+放线菌素D+环磷酰胺+多柔比星）、VAIA方案（VCR + ActD+IFM + ADM，即长春新碱+放线菌素D+异环磷酰胺+多柔比星）、VAI方案（VCR + ActD+IFM，即长春新碱+放线菌素D+异环磷酰胺）、VDC方案（VCR + doxorubicin+CPA，即长春新碱+多柔比星+环磷酰胺）、IE方案（IFM + ETP，即异环磷酰胺+依托泊苷）、EVAIA方案（ETP + VCR + ActD+IFM + ADM，即依托泊苷+长春新碱+放线菌素D+异环磷酰胺+多柔比星）。